mars 2021

Ajinomoto Bio-Pharma

Ajinomoto Bio-Pharma

Financial Advisor (Buy side)

Results Healthcare Advised Ajinomoto Bio-Pharma Services on the Licencing of its Crystalomics Formulation Technology to Kyowa Kirin

More Like This

En attente d'achèvement

Neuronetics

Financial Advisor to Neuronetics on its Announced Merger with Greenbrook TMS
novembre 2024

UCB

Advisor to UCB on the Sale of the Rights of Nootropil® and Atarax® Products to Advanz Pharma
octobre 2024

Telemos Capital

Exclusive Financial Advisor (Buy side)

Afficher les transactions Healthcare